Navigation Links
Lilly Reports First-Quarter 2011 Results
Date:4/18/2011

pite a significant decline in Gemzar sales due to generic competition. This revenue growth allowed us to make necessary investments in research and development to address the challenges of upcoming patent expirations. We are on track to deliver on our 2011 headcount and expense reduction targets, as well as our goal of having at least ten potential new medicines in Phase 3 clinical development by the end of this year."

Key Events Over the Last Three Months

  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of exenatide 2 mg powder and solvent for prolonged release suspension for injection (proposed trade name Bydureon) in the European Union for the treatment of type 2 diabetes in combination with certain oral therapies. The CHMP's positive opinion is now referred for final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
  • Late last week, the company received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), under investigation for the treatment of exocrine pancreatic insufficiency (EPI). The complete response letter communicated the need for Lilly to conduct an additional clinical trial prior to a re-submission. The company will be working diligently to address the agency's questions.
  • The company announced that Axiron® (testosterone) topical solution is available in pharmacies throughout the U.S.
  • The company received a complete response letter from the FDA for the NDA for Amyvid™ (florbetapir F 18 injection), a Positron Emission Tomography (PET) imaging agent under investigation for the detection of beta-amyloid plaque in the brain
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
    4. Lilly Receives NCQA Design Certification for Depression Care Management Program
    5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
    6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
    7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
    8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
    9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
    10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
    11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
    (Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
    (Date:11/21/2014)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... Annual Healthcare Conference in New York City . ... for 8:00 am EST (5:00 am PST) on Tuesday December 2, ... accessed via the Investor Relations page of the Depomed website at ... for 30 days on the company,s website. About ...
    Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
    ... April 11, 2012  Blue Mountain Hospital has used an electronic ... announced plans to swap out its original technology with an ... "We were lucky to start out as a ... are using simply is not meeting all of our needs," ...
    ... BAY, Wis., April 11, 2012   IOD Incorporated™, ... health systems, and physician practices, today announced its response ... a proposed rule to delay ICD-10 from October 1, ... http://photos.prnewswire.com/prnh/20111207/CG18689LOGO ) According to HHS regulations ...
    Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
    (Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
    (Date:11/22/2014)... York, NY (PRWEB) November 22, 2014 ... Therapeutics Goods Administration (TGA) approved it for use ... was approved and listed within the Therapeutic Goods ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione will ... a biotech specialist that sources and imports fine ...
    (Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
    (Date:11/22/2014)... TX (PRWEB) November 22, 2014 ... (ICS) as the complaint that the individual has ... for voiding. The report “Nocturia – Pipeline Review, ... development for Nocturia, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
    (Date:11/22/2014)... York (PRWEB) November 22, 2014 A ... morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and ... signatures since the end of October, Bernstein Liebhard LLP ... the petition as of November 21st, 2014. That represents ... 86,042 supporters had signed on to the campaign.* , ...
    Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
    ... than Alzheimer,s patients, healthy controls , , MONDAY, Oct. 13 ... than healthy people or Alzheimer,s patients to have vitamin ... of Medicine in Atlanta. , They compared vitamin D ... 99 healthy people matched for age and other factors. ...
    ... greater effect on women, study found , , MONDAY, Oct. 13 ... your brain shrinks, a new study has found. , ... you,re going to hurt your brain," said Rajesh Miranda, an ... A&M Health Science Center College of Medicine. "This is something ...
    ... AMERIGROUP Foundation,today announced a contribution in support of ... enhance the organization,s vocational,training program., SCHI is ... underprivileged children with special needs from,throughout New Jersey. ... suffering of the,most vulnerable members of the community. ...
    ... a Healthy Spine, PLANO, Texas, Oct. 13 ... Back Institute shares "Nine for Your Spine." The,release of ... October 16, 2008., National Spine Health Day was ... the most effective means of reducing the,prevalence and severity ...
    ... System, Supports Global Pharma Client in Closing ... CHESTER, Pa., Oct. 13 Modevity, LLC announced,today ... Imperium technology to become the primary platform for ... for their new product video content. Imperium is ...
    ... ANNAPOLIS, Md., Oct. 13 The National Coalition ... concerns over,the National CT Colonography Study published September ... evidence must be closely evaluated, and,patients need to ... risks. The National Coalition reminds patients that Colonoscopy,remains ...
    Cached Medicine News:Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:Excess Drinking Shrinks the Brain 2Health News:AMERIGROUP Foundation Supports the School for Children with Hidden Intelligence 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 3Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
    ... advancement in supralaryngeal airway management., ,The CobraPLA ... the hypopharynx where it abuts the structure of ... head design of the distal end of the ... epiglottis out of the way, facilitating ventilation through ...
    Robertazzi Amber Latex Free Nasal Airways are manufactured from natural amber latex. Soft, flexible maximizing comfort....
    Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
    Extra soft for patient comfort., ,The Argyle® Nasopharyngeal Airway provides an open airway to make suctioning and bronchoscopy easier, safer, and less traumatic....
    Medicine Products: